Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 29, 2025 16:15 ET | Source: Emergent BioSolutions

Emergent BioSolutions Reports Third Quarter 2025 Financial Results

Third Quarter 2025 Total Revenues of $231.1 million, above the high end of Q3 guidance by $21.0 millionThird Quarter 2025 Net Income of $51.2 million and Net Income Margin of 22%Third Quarter 2025...
October 28, 2025 08:00 ET | Source: Emergent BioSolutions

Emergent BioSolutions Releases New Survey Findings Revealing Heightened Concerns About Biological Threats and U.S. Preparedness

GAITHERSBURG, Md., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the results of a new survey1 of approximately 250 U.S. policy opinion leaders showing that...
October 08, 2025 07:45 ET | Source: Emergent BioSolutions

Emergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025

GAITHERSBURG, Md., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, October 29, 2025, at 5:00 pm eastern time to discuss the...
September 24, 2025 16:05 ET | Source: Emergent BioSolutions

Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone

GAITHERSBURG, Md., Sept. 24, 2025 (GLOBE NEWSWIRE) -- In recognition of several observances in September meant to keep the national opioid poisoning epidemic front and center, Emergent BioSolutions...
September 19, 2025 08:34 ET | Source: Emergent BioSolutions

Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner

GAITHERSBURG, Md., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured new purchase orders from an international government partner for a...
September 15, 2025 08:35 ET | Source: Emergent BioSolutions

Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain

GAITHERSBURG, Md., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received a $17 million contract modification from the Biomedical Advanced Research...
September 09, 2025 07:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness

GAITHERSBURG, Md., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that a contract modification has been executed in the amount of $56 million to supply...
September 02, 2025 07:40 ET | Source: Emergent BioSolutions

Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use

GAITHERSBURG, Md., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received a $30 million contract modification from the Biomedical Advanced Research...
August 29, 2025 08:05 ET | Source: Emergent BioSolutions

Emergent BioSolutions Underscores Continued Support of Increasing Naloxone Awareness Through Public Education Campaign on International Overdose Awareness Day

Pro Football Hall of Famer and Ready to Rescue campaign spokesperson, Emmitt Smith, and Release Recovery Founder/CEO, Zac Clark, plan to visit several U.S. college campuses to educate on opioid...
August 27, 2025 08:01 ET | Source: Emergent BioSolutions

Emergent BioSolutions to Participate in Upcoming Investor Conferences

GAITHERSBURG, Md., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the following...